The cell composition of the final product matters when developing or manufacturing a T cell based cancer therapy such as CAR-T or TCR-T. Cell composition ultimately impacts the effectiveness and longevity following treatment, as well as the safety of the therapy itself.
T cell based treatments that are enriched in more stemlike T cells have been shown to last longer in vivo and be more effective and safer for patients. Stem cell memory T cells, or TSCMs, are one of the most important types of these stemlike T cells. As such, targeted, intentional expansion of TSCMs and enrichment in the final adoptive T cell based product is one of the most promising strategies for making improved and better T cell based cancer therapies.
Connect with Nanotein today!